Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Beovu | brolucizumab | Diabetic macular edema | Reimburse with clinical criteria and/or conditions | Complete | ||
| Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete | ||
| Increlex | mecasermin | Severe primary insulin-like growth factor-1 deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bijuva | estradiol and progesterone | Vasomotor symptoms associated with menopause | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sarclisa | isatuximab | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trodelvy | sacituzumab govitecan | Locally advanced or metastatic triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024